Drugs /

lmp744

Back to Drugs List

Overview

NCI Definition [1]:
An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.

Clinical Trials

View Clinical Trials for lmp744

Lmp744 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lmp744, 1 is phase 1 (1 open).

Lymphoma and malignant solid tumor are the most common diseases being investigated in lmp744 clinical trials [2].

Drug Details

Synonyms [2]:
5h-(1,3)dioxolo(5,6)indeno(1,2-c)isoquinoline-5,12(6h)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-, indenoisoquinoline lmp744, lmp-744, topoisomerase-1 inhibitor lmp744
Drug Target(s) [2]:
TOP1
NCIT ID [1]:
C127900

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.